Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dalvance: First QIDP Antibiotic Breaks New Regulatory Ground; Label Doesn’t

Executive Summary

Durata has post-marketing requirements to continue resistance-related studies, but its label includes stewardship language similar to other antibiotics.

You may also be interested in...



Dalvance Protocol Accord With FDA + Actavis Marketing = Home Run?

With a Special Protocol Agreement and an experienced sales team lined up, all the firm has to do now is get hospitals excited about an expensive antibiotic in a highly-genericized market.

Cubist’s Sivextro To Beat Durata’s Dalvance To Antibiotic Market

Second QIDP antibiotic is first to market; Cubist will stress shorter term dosing over available therapies and thinks it can rely on efficient marketing strategy for commercial success.

FDA Adds Three “Qualifying Pathogens” For Potential Antibiotic Incentives

Final rule includes a total of 21 pathogens, but agency notes a drug intended to treat a pathogen on the list is not guaranteed a QIDP designation for priority review and potential added marketing exclusivity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel